Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W E Haefeli

Showing results (41-50 of 132) with videos related to

Pageof 14
Sort By:
European Journal of Clinical Pharmacology|February 23, 1999
Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activitiesP Fuchs, W E Haefeli, H R Ledermann, et al.
Schweizerische Medizinische Wochenschrift|November 11, 1999
[Conviction as a basis for compliance and strategies for improving compliance]I Arnet, R A Schoenenberger, R Spiegel, et al.
Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis|December 8, 1992
[Drug-induced hyperprolactinemia and galactorrhea]M Bozzolo, W E Haefeli, G Noll, et al.
Clinical Pharmacology and Therapeutics|April 4, 2013
Cytochrome P450-3A phenotyping using midazolam is not altered by OATP1B1 polymorphismsV C Ziesenitz, J Weiss, W E Haefeli, et al.
Journal of Vascular Surgery|April 18, 1998
Functional activity and transmembrane signaling mechanisms after cryopreservation of human internal mammary arteriesE Müller-Schweinitzer, P Stulz, H Striffeler, et al.
Journal of Vascular Surgery|April 1, 1997
Functional recovery of human mesenteric and coronary arteries after cryopreservation at -196 degrees C in a serum-free mediumE Müller-Schweinitzer, M J Mihatsch, M Schilling, et al.
Clinical Pharmacology and Therapeutics|September 20, 2013
CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteersC Markert, J Burhenne, J Weiss, et al.
Journal of Cardiovascular Pharmacology|May 1, 1990
Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivoW E Haefeli, M J Bargetzi, F Follath, et al.
British Journal of Pharmacology|May 24, 2000
The mechanism of cryoinjury: In vitro studies on human internal mammary arteriesE Müller-Schweinitzer, W Brett, H R Zerkowski, et al.
Pharmacoepidemiology and Drug Safety|April 26, 2007
Optimizing information on drug exposure by collection of package code information in questionnaire surveysR Quinzler, S P W Schmitt, J Szecsenyi, et al.
Pageof 14

Showing results (41-50 of 132) with videos related to

Sort By:
Pageof 14
European Journal of Clinical Pharmacology|February 23, 1999
Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activitiesP Fuchs, W E Haefeli, H R Ledermann, et al.
Schweizerische Medizinische Wochenschrift|November 11, 1999
[Conviction as a basis for compliance and strategies for improving compliance]I Arnet, R A Schoenenberger, R Spiegel, et al.
Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis|December 8, 1992
[Drug-induced hyperprolactinemia and galactorrhea]M Bozzolo, W E Haefeli, G Noll, et al.
Clinical Pharmacology and Therapeutics|April 4, 2013
Cytochrome P450-3A phenotyping using midazolam is not altered by OATP1B1 polymorphismsV C Ziesenitz, J Weiss, W E Haefeli, et al.
Journal of Vascular Surgery|April 18, 1998
Functional activity and transmembrane signaling mechanisms after cryopreservation of human internal mammary arteriesE Müller-Schweinitzer, P Stulz, H Striffeler, et al.
Journal of Vascular Surgery|April 1, 1997
Functional recovery of human mesenteric and coronary arteries after cryopreservation at -196 degrees C in a serum-free mediumE Müller-Schweinitzer, M J Mihatsch, M Schilling, et al.
Clinical Pharmacology and Therapeutics|September 20, 2013
CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteersC Markert, J Burhenne, J Weiss, et al.
Journal of Cardiovascular Pharmacology|May 1, 1990
Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivoW E Haefeli, M J Bargetzi, F Follath, et al.
British Journal of Pharmacology|May 24, 2000
The mechanism of cryoinjury: In vitro studies on human internal mammary arteriesE Müller-Schweinitzer, W Brett, H R Zerkowski, et al.
Pharmacoepidemiology and Drug Safety|April 26, 2007
Optimizing information on drug exposure by collection of package code information in questionnaire surveysR Quinzler, S P W Schmitt, J Szecsenyi, et al.
Pageof 14